Treatment
Standard medical treatment clinical trials
We’re tracking 537 recruiting studies that include Standard medical treatment, each written for real people, not researchers, below.
Recruiting studies
- NCT07267078RecruitingPhase 2
Tuvonralimab and Iparomlimab before surgery for bile duct cancer
This trial tests two immunotherapy drugs (Tuvonralimab and Iparomlimab) given before surgery to shrink bile duct cancers that are borderline removable. The goal is to make the tumor easier to remove completely and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07206108Recruiting
Crown vs post-core for large tooth repairs after root canal
This trial compares two ways to fix large holes in premolars after root canal treatment: a modified crown attached to the remaining tooth, or a personalized post-and-crown. It looks for people with good oral health whose tooth has enough strong structure left for a successful repair.
ChinaAges 18–65 - NCT07001956RecruitingEarly Phase 1
UTAA91 injection for difficult rheumatoid arthritis
This trial tests a new injection called UTAA91 for people with hard-to-treat rheumatoid arthritis. It's for those who have tried standard treatments without success.
Wuhan, HubeiAges 18 years+ - NCT05240976RecruitingPhase 2
Testing add-on treatments for very treatment-resistant schizophrenia
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
TaichungAges 18–65 - NCT02235857Recruiting
Device treatment study for children with focal segmental kidney scarring
This trial studies a medical device (the Liposorber LA-15) in children with focal segmental glomerulosclerosis (FSGS), a kidney condition that can cause heavy protein loss in the urine. It may help by improving disease control when standard treatments have not worked, were hard to tolerate, or can’t be used.
Loma Linda, CaliforniaAges Up to 21 years - NCT06467097RecruitingPhase 3
Drug therapy vs. drug therapy plus radiation for limited kidney cancer
This trial tests whether adding radiation to standard drug therapy helps control kidney cancer that has spread to a few spots (oligometastatic). It is for people with clear cell renal cell carcinoma who have up to 5 metastases.
SeoulAges 20–80 - NCT05865600Recruiting
PET/CT guided planning for treatment in chronic coronary disease
This trial uses a heart scan (PET/CT) to better estimate blood flow in people with long-term coronary artery disease. It aims to help doctors choose the best treatment strategy and decide who may need more invasive testing or procedures.
Herning, Central JutlandAges 18 years+ - NCT04946253Recruiting
Help in teams to improve care for kids with behavior problems
This study tests a program to help pediatric practice teams work together better, led by clinic leadership and managers, to support children’s behavioral health. Caregivers of children ages 5–12 with behavior problems may also be involved to connect care at home and in the clinic.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06104215RecruitingEarly Phase 1
BGT007H cells for advanced digestive cancer
This trial tests a new cell therapy called BGT007H for people with advanced digestive tract cancers (esophagus, stomach, pancreas, or colon) that have not responded to or stopped working after at least two prior treatments. The goal is to see if this therapy can help shrink tumors or slow the disease.
Xuzhou, JiangsuAges 18–70 - NCT07632001Recruiting
Miro3D Wound Matrix for Diabetic Foot Ulcers
This trial tests a new wound-healing product called Miro3D to help diabetic foot ulcers heal better. You would receive this product along with standard wound care to see if it helps your ulcer close faster than standard treatment alone.
Phoenix, ArizonaAges 18 years+ - NCT07453368RecruitingPhase 2
Orelabrutinib for relapsed or hard-to-treat AIHA
This trial tests a targeted pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that has come back or not responded to standard treatments. It may help control your immune system's attack on your red blood cells.
Beijing, Beijing MunicipalityAges 18–85 - NCT06051760RecruitingPhase 1
NV-001 for advanced solid tumors after standard treatments
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07210086RecruitingPhase 2
PET scans to guide radiation for limited metastatic prostate cancer
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Duarte, CaliforniaAges 18 years+ - NCT06641115Recruiting
Integrated treatment for opioid use disorder and PTSD
This study tests a combined therapy for people with both opioid use disorder and PTSD. It aims to help you manage both conditions together, rather than treating them separately.
Charleston, South CarolinaAges 18–70 - NCT04762992Enrolling by invitationPhase 3
Heparin medicine for early slow fetal growth in one pregnancy
This study tests whether a blood-thinner medicine (LMWH) can improve outcomes for people carrying a singleton baby with early signs of slow growth. It compares LMWH against standard care to see if treatment helps the baby and pregnancy stay safer.
LisbonAges 18 years+ - NCT04701684Recruiting
Fast-stroke treatment workflow study to save minutes to clot removal
This study tests whether a streamlined hospital workflow can reduce the time it takes to reopen blocked blood vessels during very fast stroke treatment. Faster treatment may help more brain tissue be saved by getting endovascular (clot-removal) therapy started sooner.
Jacksonville, FloridaAges 18 years+ - NCT07286240RecruitingPhase 2
QL1706 with chemo and anlotinib for recurrent ovarian cancer
This trial tests a combination of a new immunotherapy drug (QL1706), chemotherapy, and a targeted therapy (anlotinib) for ovarian cancer that has come back after standard platinum treatment. The goal is to see if this triple therapy can shrink tumors or slow the cancer's return.
Guangzhou, GuangdongAges 18–70 - NCT07455019RecruitingPhase 2
Immunotherapy, targeted therapy, radiation, and chemo for limited spread esophageal cancer
This trial tests a combination of an immunotherapy drug (bemosubaymab), a targeted therapy (anlotinib), radiation therapy, and chemotherapy for patients with esophageal cancer that has spread to a limited number of spots (no more than 5). The goal is to see if this combination can shrink or control the cancer.
Nanjing, JiangsuAges 18 years+ - NCT05817955RecruitingPhase 2
Azacitidine plus ruxolitinib for higher-risk MDS/MPN
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
Nanjing, JiangsuAges 18–80 - NCT07656116RecruitingPhase 1
Oncolytic virus therapy for advanced solid tumors
This trial tests a virus-based treatment for people with advanced solid tumors that haven't responded to standard treatments. The virus is designed to infect and kill cancer cells while leaving healthy cells alone.
Langfang, HebeiAges 18 years+ - NCT07529145Recruiting
Heart and Lung Fitness Testing During Lung Cancer Treatment
This study measures how well your heart and lungs work before and during lung cancer treatment using an exercise test. The goal is to understand how cancer treatment affects your physical fitness and help doctors better monitor your health.
Bialystok, Podlaskie VoivodeshipAges 18 years+ - NCT07309900RecruitingPhase 1
Testing IASO208 for relapsed or hard-to-treat B-cell cancers
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
Wuhan, HubeiAges 18–75 - NCT07294625RecruitingEarly Phase 1
Gene therapy for relapsed/refractory multiple myeloma
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
Zhengzhou, HenanAges 18 years+ - NCT06916663Recruiting
Upper body vs. combined exercise during diabetic foot ulcer treatment
This trial compares two exercise programs for people with diabetic foot ulcers: one that uses only upper body exercises and one that combines upper body with non-weight bearing lower body exercises. The goal is to see which approach helps healing while keeping weight off the foot.
CairoAges 18–65
Common questions
- Are there clinical trials studying Standard medical treatment?
- Yes. Clin2 currently lists 537 recruiting studies that include Standard medical treatment, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Standard medical treatment trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Standard medical treatment an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Standard medical treatment or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.